Glaucoma

Glaucoma belongs to the category of optic neuropathies—diseases that damage the optic nerve, the cable-like structure that carries visual signals from the eye to the brain. The optic nerve is composed of more than one million nerve fibers called retinal ganglion cells (RGCs), and glaucoma progressively destroys these fibers in a characteristic pattern. Because the nerve fibers that are damaged first serve peripheral vision, and because the brain compensates for the early loss, most people with glaucoma have no idea the disease is advancing until it has already caused substantial, irreversible damage. This is why glaucoma is called “'the silent thief of sight.”

Glaucoma is not a single disease but an umbrella term for a group of progressive eye conditions—called glaucomatous optic neuropathies—that share one hallmark: the progressive degeneration of retinal ganglion cells and their axons within the optic nerve, producing a characteristic scooped-out appearance of the optic nerve head called “cupping," along with corresponding losses of visual field. The most common form (primary open-angle glaucoma) is caused by increased resistance to the outflow of the eye’s natural fluid (aqueous humor), which raises the pressure inside the eye (intraocular pressure—IOP). However, glaucoma can also occur at entirely normal eye pressure levels—and normal eye pressure alone does not exclude the diagnosis. The disease can affect one or both eyes and, without treatment, progresses to blindness.

Glaucoma is the leading cause of irreversible blindness worldwide, currently affecting approximately 80 million people globally—a number projected to reach 111.8 million by 2040 as the world’s population ages. In the United States, approximately three million people are affected, at an estimated healthcare cost of $2.5 billion annually. Between 10 and 50% of people with glaucoma do not know they have it. Approximately 10% of the global glaucoma population is bilaterally blind despite available treatments. Glaucoma is not curable—vision that has been lost cannot be restored—but early diagnosis and consistent treatment can halt or significantly slow its progression. Glaucoma disproportionately affects Black and Hispanic/Latino Americans, who face both higher prevalence rates and higher rates of undetected disease, underscoring the importance of equity-centered screening and access to care.

Physicians classify glaucoma along two primary axes: mechanism (open-angle versus angle-closure, describing whether the drainage channel of the eye is physically obstructed) and etiology (primary, meaning no other identified cause; secondary, meaning caused by another identifiable condition, or developmental/congenital, meaning present from birth or early childhood). Each category has distinct clinical features, treatment priorities, and risk profiles.

Glaucoma’s biological basis is incompletely understood, but the dominant mechanism across most forms is elevated IOP causing mechanical stress on the optic nerve, combined with secondary neurodegenerative cascades that continue even when pressure is later controlled. Non-pressure-dependent mechanisms are especially prominent in normal-tension glaucoma.

The eye continuously produces a clear fluid called aqueous humor in the ciliary body. This fluid flows through the pupil into the anterior chamber and drains out through two pathways: the conventional pathway (through the trabecular meshwork into Schlemm’s canal and then into veins), which handles 70–90% of outflow, and the uveoscleral pathway (across the ciliary muscle and into the suprachoroidal space), which handles the remainder. In primary open-angle glaucoma, age-related decline in trabecular meshwork cell populations, reduced cellular housekeeping (phagocytosis), accumulation of debris, and excess extracellular matrix deposition driven by the inflammatory signaling molecule transforming growth factor (TGF)-beta increase drainage resistance. Disrupted nitric oxide signaling in trabecular meshwork cells further reduces their ability to relax and facilitate fluid transport. The result is a steady rise in IOP. In angle-closure glaucoma, the mechanism is different: the lens pushes against the iris, trapping aqueous humor behind the iris (pupillary block), which causes the iris to bow forward and physically seal the drainage angle.

Chronically elevated IOP applies mechanical stress and strain to the lamina cribrosa—a sieve-like collagen meshwork at the back of the eye through which the retinal ganglion cell (RGC) axons exit on their way to the brain. The lamina cribrosa is the mechanically weakest point of the eye wall, and it is the primary site of glaucomatous injury. The sequence of events is: elevated IOP deforms and remodels the lamina cribrosa, compressing and physically disrupting the RGC axons passing through it; the compressed axons lose the ability to transport nutrients and neurotrophic support factors (including brain-derived neurotrophic factor—BDNF and nerve growth factor—NGF) between the eye and the brain; RGC mitochondria fail under the elevated energy demand; supporting cells in the optic nerve head (microglia and astrocytes) become activated and drive further scarring; retinal ischemia creates oxidative stress and excess glutamate release, which is toxic to neurons (excitotoxicity); and ultimately RGCs undergo programmed cell death (apoptosis). By the time standard visual field testing detects a defect, 30–50% of the retinal ganglion cells have already been lost—which is why structural imaging that detects nerve fiber layer thinning before functional loss is so clinically important.

In NTG, a low cerebrospinal fluid pressure in the optic nerve’s surrounding fluid space creates a large pressure difference across the lamina cribrosa—effectively mimicking the effects of elevated IOP even when IOP is normal. Vascular dysregulation—impaired ocular blood flow, vasospasm, and endothelial dysfunction—is also implicated. Specific NTG-associated gene mutations, including optineurin (OPTN) and tank-binding kinase 1 (TBK1), dysregulate tumor necrosis factor (TNF)-alpha signaling, leading to proapoptotic gene expression and RGC death at entirely normal IOP levels.

Multiple genes contribute to glaucoma susceptibility. Myocilin (MYOC) mutations cause a misfolded protein to accumulate inside trabecular meshwork cells, creating endoplasmic reticulum (ER) stress and IOP elevation; MYOC mutations account for 3–5% of adult POAG and most cases of juvenile open-angle glaucoma. OPTN and TBK1 mutations cause familial normal-tension glaucoma through dysregulated neuroinflammatory signaling. LOXL1 variants underlie exfoliation glaucoma by impairing the elastin maintenance that normally keeps fibrillar material from accumulating in the trabecular meshwork. CYP1B1 loss-of-function mutations are the most common cause of primary congenital glaucoma. FOXC1 and PITX2 mutations cause anterior segment dysgenesis. The caveolin gene variants (CAV1 and CAV2) dysregulate nitric oxide production in trabecular meshwork cells. More than a dozen additional genetic loci have been identified across POAG, PACG, and NTG through genome-wide association studies.

Risk factors for glaucoma fall into two broad categories: non-modifiable demographic and genetic factors, and modifiable ocular and medical factors. Understanding individual risk profiles is essential for determining who needs screening and how aggressively to treat.

• Age: the single strongest risk factor for POAG. Prevalence is approximately 0.6% in adults aged 40 to 49 and rises to 8.3% by age 80 or older. Risk roughly doubles each decade after 40.
• African American race: Black Americans have approximately four times the POAG prevalence of age-matched white Americans (4.97% versus 1.44% in the Baltimore Eye Study). Among Black Americans aged 50 to 59, POAG prevalence is 4%; by ages 80 to 89, it reaches 13%. Black Americans are also more likely to be at an advanced stage when first diagnosed. This disparity reflects both biological differences in optic nerve vulnerability and longstanding inequities in access to ophthalmic screening and care.
• Hispanic and Latino ethnicity: POAG prevalence of 4.74% in the Los Angeles Latino Eye Study, comparable to that of Black Americans. Community studies find 62–75% of Hispanic individuals with glaucoma are undiagnosed, reflecting a significant unmet screening need.
• Asian ethnicity: People of Asian ethnicity have a higher prevalence of primary angle-closure glaucoma due to anatomical predisposition: shorter axial length, shallower anterior chambers, thicker and more anteriorly positioned lenses, and greater iris curvature compared to other populations.
• Female sex: Females carry a higher primary angle-closure glaucoma (PACG) risk than males due to smaller anterior segment anatomy.
• Family history: Having a first-degree relative (parent, sibling, child) with glaucoma significantly elevates personal risk. This applies to all major glaucoma subtypes.
• Genetic mutations: MYOC mutations (JOAG and adult POAG), CYP1B1 mutations (congenital glaucoma), OPTN and TBK1 mutations (familial NTG), and FOXC1/PITX2 mutations (developmental glaucoma) each carry high penetrance in affected families.

• Elevated intraocular pressure/ocular hypertension: the primary modifiable biomarker and the only proven treatment target. However, 25–50% of glaucoma patients present with IOP in the normal range, so normal IOP does not exclude diagnosis or eliminate risk.
• Thin central corneal thickness: A thinner-than-average cornea (below 555 micrometers) is an independent risk factor for POAG progression and also leads to underestimation of true IOP when measured by standard applanation tonometry.
• Large or asymmetric cup-to-disc ratio: A cup-to-disc ratio above 0.6 or asymmetry of more than 0.2 between the two eyes is a warning sign requiring evaluation.
• Disc hemorrhage: A small bleeding spot at the rim of the optic disc is a strong predictor of glaucomatous progression, particularly in NTG.
• High myopia: This is associated with structural vulnerability of the optic nerve head to pressure-related damage.
• Low cerebrospinal fluid pressure: This is a specific risk factor for normal-tension glaucoma.
• Anatomic angle-closure risk factors: Shallow central anterior chamber depth, thicker or anteriorly positioned crystalline lens, short axial eye length, smaller anterior chamber area, and greater iris curvature all predispose to angle closure.
• Corticosteroid medications: Topical ophthalmic, periocular, intravitreal, systemic, and even inhaled steroids can raise IOP through increased trabecular meshwork resistance. All patients on chronic corticosteroid therapy should have their intraocular pressure monitored.
• Certain other medications: Anticholinergic drugs and topiramate (a seizure and migraine medication that can induce a myopic shift and ciliary body effusion) can precipitate acute angle closure in anatomically predisposed eyes. Patients with narrow angles should discuss all medications with their ophthalmologist.

There is currently no recommendation for universal population-level screening for glaucoma—the U.S. Preventive Services Task Force determined that the overall evidence is insufficient to evaluate the balance of benefits and harms of mass asymptomatic adult screening. However, risk-based targeted screening for high-risk populations is strongly supported and widely recommended by the National Eye Institute (NEI) and the Centers for Disease Control and Prevention (CDC).

The following individuals should have a comprehensive dilated eye examination every one to two years: all adults over age 60; Black Americans over age 40; anyone with a first-degree family member with glaucoma who has not had a dilated eye examination in the past two years, and patients on chronic corticosteroid therapy. The comprehensive dilated eye examination is the gold standard for glaucoma detection—it includes intraocular pressure measurement, a dilated evaluation of the optic nerve head, visual field testing, and angle assessment. Community-based telemedicine programs (including NYC-SIGHT, MI-SIGHT, and AL-SIGHT) have demonstrated that technician-performed screening with remote ophthalmologist review can successfully reach underserved populations; in the NYC-SIGHT program, 20% of participants were identified as glaucoma suspects or had manifest glaucoma.

Among diagnosed POAG patients, American Academy of Ophthalmology (AAO) guidelines call for a minimum of annual visual field testing to monitor for progression—yet more than 75% of U.S. patients currently receive less than one visual field test per year, representing a critical gap in follow-up care.

Glaucoma cannot be prevented in most forms—genetic predisposition underlies the majority of cases and cannot be altered. Prevention strategy focuses on secondary prevention (halting or slowing irreversible progression once the disease is identified) and on risk reduction for angle-closure glaucoma specifically. Genetic counseling is appropriate for families with identified high-penetrance mutations, including MYOC, CYP1B1, FOXC1, and PITX2. Specific prevention strategies include:

• Prophylactic laser peripheral iridotomy (LPI): For individuals identified as angle-closure suspects (narrow angle, primary angle-closure suspect, or primary angle closure), LPI creates a small opening in the peripheral iris to bypass pupillary block, preventing the iris from sealing the drainage angle. This is a highly effective outpatient laser procedure that can prevent both acute angle-closure crisis and progression to PACG.
• Cataract extraction: Removing a thickening crystalline lens significantly widens the anterior chamber angle and reduces IOP in angle-closure patients. Lens extraction is strongly protective against PACG development.
• Minimizing corticosteroid use: Using the lowest effective dose, choosing nonsteroidal anti-inflammatory alternatives where possible, and monitoring IOP during corticosteroid therapy prevents steroid-induced glaucoma.
• Avoiding angle-closure triggers in susceptible individuals: Anticholinergic drugs and topiramate can precipitate acute angle closure in anatomically predisposed eyes. Known narrow-angle patients should discuss these medications with their ophthalmologist before use.
• Aerobic physical activity: In patients with treated glaucoma, greater physical activity (approximately 5,000 additional daily steps) is associated with approximately 10% slower visual field loss rate. Regular exercise also supports cardiovascular health and optimal ocular perfusion pressure.
• Blood pressure and cardiovascular health optimization: Adequate ocular perfusion pressure (the difference between blood pressure and IOP) is important for maintaining optic nerve blood supply, particularly in NTG. Manage hypertension and cardiovascular risk factors under physician guidance.
• Strict adherence to prescribed IOP-lowering therapy: For patients already diagnosed with glaucoma, consistent medication use is the most impactful factor within a patient’s control for preventing further vision loss.

The hallmark of glaucoma—particularly the open-angle forms—is the near-complete absence of symptoms in early to moderate stages. Glaucoma earns its name as “the silent thief of sight” precisely because vision loss is painless, gradual, and first affects peripheral vision, which the brain compensates for so effectively that most people notice nothing until the damage is extensive. As many as half of all people with glaucoma are unaware they have the disease. By the time a standard visual field test can detect a defect, 30–50% of the optic nerve’s retinal ganglion cells have already been permanently lost.

Open-angle glaucoma (POAG, NTG, exfoliation glaucoma, pigmentary glaucoma) typically produces no symptoms until the disease is moderate to advanced:

• No symptoms in early stages: The only way to detect glaucoma in its earliest, most treatable stage is through a scheduled dilated eye examination.
• Gradual, painless loss of peripheral (side) vision: Open-angle glaucoma begins in mid-peripheral zones; the portion of vision closest to the nose is typically affected first. Patients may not notice because the other eye compensates.
• Superior arcuate visual field defects: classical early pattern of vision loss following the curved path of the nerve fiber layer; detected on formal visual field testing before most patients are aware of any change
• Nasal step: This is a visual field defect that stops abruptly at the horizontal midline on the nasal (nose) side; a characteristic glaucoma pattern.
• Progressive tunnel vision: As more nerve fibers are lost, vision constricts toward a small central island, eventually leaving only a narrow central field. The peripheral world gradually disappears.
• Difficulty noticing pedestrians or vehicles approaching from the side: This is a common first functional complaint in patients with moderate disease.
• Reduced contrast sensitivity and difficulty navigating in low light: There is impaired scotopic (dim-light) function as rod-serving RGCs are lost.
• Total blindness: This is the end stage of untreated progressive glaucoma.

Acute angle-closure crisis presents with dramatic, unmistakable symptoms. This is an ophthalmic emergency—permanent blindness can occur within hours without treatment. If the following symptoms develop, seek emergency care immediately:

• Sudden, severe, intense eye pain—the hallmark symptom
• Severe headache on the same side as the affected eye
• Nausea and vomiting
• Blurred vision from corneal swelling
• Halos around lights—caused by corneal epithelial edema diffracting light
• Red eye—from conjunctival and episcleral blood vessel dilation
• Light sensitivity (photophobia)On examination: IOP typically above 30 to 50 mmHg; mid-dilated, poorly reactive pupil; hazy or cloudy cornea; shallow anterior chamber

Chronic primary angle-closure is often asymptomatic and clinically similar to POAG in its gradual visual field loss. Some patients experience intermittent subacute episodes of transient blurred vision, mild eye ache, and halos around lights—typically in dim light when the pupil dilates and partially closes a narrow angle. These transient symptoms should prompt urgent evaluation.

• In infants and young children with congenital glaucoma: The most visible signs are an enlarged eye or eyes (buphthalmos—the globe is enlarged because pressure stretches the infant eye wall), excessive tearing (epiphora), avoidance of light (photophobia), involuntary eyelid closing (blepharospasm), and cloudiness of the cornea visible as a hazy or milky appearance. Horizontal curved lines across the inner cornea, called Haab’s striae—stretch marks in the inner corneal layer—may also be visible. Parents of newborns and infants should be aware that cloudy, very large, or excessively tearful eyes warrant prompt ophthalmological evaluation.
• In older children and adolescents with juvenile open-angle glaucoma or developmental glaucoma: Disease is usually entirely asymptomatic and detected only during family screening or incidentally. Very high IOP may occasionally cause intermittent headache or eye ache. Visual field loss may be substantial before it is noticed.
• In adults with POAG, NTG, or secondary glaucoma: Symptoms are typically absent until significant visual field loss has occurred. Adults may first notice difficulty detecting objects in peripheral vision—misjudging distance to objects to the side, bumping into furniture, missing pedestrians—or a reduced ability to drive safely at night.
  
  In older adults, increasing lens thickness with age can progressively narrow an already anatomically predisposed angle, increasing the risk of subacute or acute angle-closure episodes. Intermittent halos, blurring, and mild eye discomfort in dim light should prompt evaluation for narrow angles.

• Exfoliation syndrome and glaucoma: Visible grayish-white dandruff-like deposits on the surface of the lens capsule and the pupil margin are seen on slit-lamp examination. These deposits of abnormal fibrillar material are pathognomonic (uniquely diagnostic) for exfoliation syndrome.
• Pigmentary glaucoma: The Krukenberg spindle (a vertical brown spindle of iris pigment on the central inner corneal surface), radial spoke-pattern transillumination defects through the iris, and dense dark pigmentation of the trabecular meshwork seen on gonioscopy (direct angle examination) are the characteristic findings.
• Neovascular glaucoma: Visible abnormal new blood vessels on the iris surface (rubeosis iridis) or within the drainage angle, extremely elevated IOP, and severe eye pain. Associated with systemic ischemic conditions, including diabetic retinopathy and retinal vein occlusion.

Glaucoma is diagnosed clinically through a comprehensive ophthalmic examination—no single laboratory test, blood test, or imaging study alone confirms the diagnosis. Diagnosis requires convergence of structural evidence (optic nerve and nerve fiber layer appearance on examination and imaging) and functional evidence (visual field testing), combined with intraocular pressure measurement and assessment of the drainage angle. Early diagnosis is particularly challenging because 25–50% of glaucoma patients have IOP within the normal range at initial presentation, and because 30–50% of optic nerve fibers may be permanently lost before standard visual field testing can detect a defect. Glaucoma is diagnosed by an ophthalmologist or glaucoma subspecialist; primary care physicians play a critical referral role for high-risk patients.

• Goldmann applanation tonometry (GAT): the gold standard for IOP measurement. A calibrated prism flattens a small area of the anesthetized cornea, and the force required to do so is measured to calculate the IOP; accurate to within 1 to 2 mmHg. All patients require IOP measurement at every glaucoma visit.
• Non-contact (air-puff) tonometry: This is acceptable for mass screening; less precise than GAT.
• Rebound tonometry (Icare®): Icare® is a small probe that contacts the cornea momentarily; validated for home IOP monitoring, pediatric patients, and those unable to cooperate with standard tonometry.
• Central corneal thickness (pachymetry): The thickness of the cornea is measured by pachymetry and used to interpret IOP readings. A thin cornea (below 555 micrometers) leads to underestimation of true IOP by standard tonometry and is itself an independent risk factor for POAG progression. Pachymetry is essential for accurate IOP interpretation.

• Dilated ophthalmoscopy: The ophthalmologist examines the optic nerve head through the dilated pupil, evaluating the cup-to-disc ratio, the width and color of the neural rim tissue, the presence of disc hemorrhages (small bleeds at the disc rim that predict progression), and visible nerve fiber layer defects. A cup-to-disc ratio above 0.6 or asymmetry greater than 0.2 between the two eyes warrants further evaluation.
• Optical coherence tomography (OCT): the most widely used modern structural imaging tool for glaucoma. Spectral-domain optical coherence tomography (SD-OCT) measures the thickness of the peripapillary retinal nerve fiber layer (RNFL)—the axons of the retinal ganglion cells—around the optic disc with microscopic precision. RNFL thinning detects glaucoma three to five years before standard visual field testing reveals a defect. OCT also measures optic nerve head parameters (rim area, disc area, cup-to-disc ratio) and the macular ganglion cell complex (the RGC bodies and their processes in the central retina)—particularly sensitive for NTG and early glaucoma. Wide-field OCT capturing both the optic disc and macula simultaneously further improves diagnostic accuracy.
• OCT angiography (OCT-A): maps the density of blood vessels in the peripapillary capillary network without dye injection. Reduced vessel density correlates with glaucoma severity and with progression, and responds to IOP-lowering surgery.
• Optic disc photography and stereophotography: These provide baseline photographic documentation for longitudinal comparison; allows detection of structural change over time.

• Standard automated perimetry (Humphrey Visual Field (HVF) Analyzer 24-2 SITA Standard): the gold standard functional test for glaucoma. The patient fixes on a central target while briefly appearing lights are presented at 54 test locations within the central 24 degrees of vision. The test measures threshold sensitivity at each location, producing a map of the visual field. Glaucomatous defects appear as arcuate scotomas (curved patterns of reduced sensitivity following the nerve fiber layer), nasal steps, and paracentral defects. Summary indices include mean deviation (MD), pattern standard deviation (PSD), and the visual field index (VFI), which tracks overall field preservation over time. Standard visual field testing requires patient cooperation and has significant test-retest variability—multiple test results are needed to confirm true progression.
• Humphrey 10-2 SITA: This tests the central 10 degrees of vision at higher spatial resolution; preferred for advanced POAG or NTG with central scotomas threatening fixation.

• Gonioscopy: a mirrored contact lens placed on the anesthetized cornea allows the ophthalmologist to directly visualize the iridocorneal angle—the drainage channel of the eye—and evaluate the trabecular meshwork, Schlemm’s canal, and iris insertion. Gonioscopy is essential for distinguishing open-angle from angle-closure glaucoma, grading the degree of angle opening or closure, identifying secondary causes (pigment deposits, exfoliative material, peripheral anterior synechiae, rubeosis), and planning laser or surgical treatment.
• Anterior segment OCT (AS-OCT): non-contact cross-sectional high-resolution imaging of the angle; detects narrow and closed angles and peripheral anterior synechiae without touching the eye. Increasingly used for angle-closure suspect evaluation.
• Ultrasound biomicroscopy (UBM): high-frequency ultrasound providing detailed images of the angle and posterior structures (ciliary body, lens, choroid). Particularly useful when the cornea is opaque or when plateau iris configuration (anteriorly rotated ciliary body) is suspected.

Genetic testing is recommended for juvenile or congenital glaucoma (MYOC, CYP1B1), families with NTG (OPTN, TBK1), and anterior segment dysgenesis (FOXC1, PITX2, PAX6). Systemic workup, including fasting glucose and HbA1c, is relevant when neovascular glaucoma is present (diabetic etiology), and carotid Doppler evaluation may be performed when ocular ischemic syndrome is suspected.

Glaucoma is not curable—no treatment reverses optic nerve damage or restores vision that has already been lost. The goal of all therapies is to lower intraocular pressure toward an individualized target IOP—typically a 20–50% reduction from the untreated baseline—to slow or halt further optic nerve damage. IOP reduction is the only intervention proven to decrease both the development and progression of glaucomatous optic neuropathy across multiple landmark randomized controlled trials, including the Ocular Hypertension Treatment Study (OHTS), Early Manifest Glaucoma Trial (EMGT), Advanced Glaucoma Intervention Study (AGIS), and Collaborative Normal-Tension Glaucoma Study (CNTGS). In the OHTS, topical medications reduced the five-year conversion rate from ocular hypertension to glaucoma from 9.5% without treatment to 4.4% with treatment. Treatment must continue lifelong, and the target IOP must be reassessed at every visit based on disease stage, progression rate, and the patient’s overall health. Your ophthalmologist will design an individualized treatment plan balancing IOP-lowering efficacy, medication tolerability, and quality of life.

Topical eye drops are typically the first treatment for most adults with open-angle glaucoma. They lower IOP either by reducing aqueous humor production or by increasing its drainage, or both.

Prostaglandin analogues and prostamides are the most effective class of glaucoma drops and are given once nightly. They work primarily by increasing drainage through the uveoscleral pathway. Latanoprost (Xalatan®), bimatoprost (Lumigan®), travoprost (Travatan Z®), and tafluprost (Zioptan®) each reduce IOP by 25–35%. Local side effects include conjunctival redness, gradual lengthening and darkening of eyelashes, and in patients with mixed eye colors, irreversible darkening of the iris pigmentation. A cosmetic change called prostaglandin-associated periorbitopathy—gradual hollowing and darkening around the eyes from periorbital fat atrophy—can occur with long-term use. Systemic side effects are minimal.

Beta-adrenergic blockers reduce aqueous humor production and lower IOP by 18–26%. Timolol (Timoptic®, 0.25 or 0.5%) is the most commonly used non-selective beta-blocker. Betaxolol (Betoptic® S) is beta-1 selective and safer in mild asthma or chronic obstructive pulmonary disease (COPD). Important systemic risks: beta-blockers are contraindicated in asthma, significant COPD, second- or third-degree heart block, and bradycardia. They can mask symptoms of low blood sugar in diabetic patients. To reduce systemic absorption, closing the eye or pressing on the inner corner (nasolacrimal occlusion) for two minutes after instillation is recommended.

Alpha-2 adrenergic agonists reduce aqueous production and increase uveoscleral drainage, lowering IOP by 20–25%. Brimonidine tartrate (Alphagan® P) is the primary agent in this class. It has shown possible neuroprotective effects in preclinical studies and is a commonly used adjunct. An ocular allergic reaction occurs in 12–25% of long-term brimonidine users. Brimonidine and apraclonidine are contraindicated in infants and young children, as they can cross the blood-brain barrier and cause dangerous central nervous system (CNS) depression and respiratory arrest.

Carbonic anhydrase inhibitors (CAIs) reduce aqueous production by inhibiting an enzyme in the ciliary body. Topical agents (dorzolamide/Trusopt and brinzolamide/Azopt) lower IOP by 15–25%. Oral acetazolamide (Diamox®) is used for rapid IOP reduction in acute angle-closure crisis but is not suitable for long-term use due to side effects, including tingling in the extremities, nausea, weight loss, kidney stones, and metabolic acidosis. All CAIs are contraindicated in patients with sulfonamide allergy.

Rho-associated protein kinase (ROCK) inhibitors are a newer class that enhance conventional trabecular meshwork outflow by relaxing smooth muscle-like cells in the drainage tissue. Netarsudil (Rhopressa®, 0.02%) was U.S. Food and Drug Administration (FDA)-approved in 2017. It is given once nightly and reduces IOP by 20–25%. It also reduces episcleral venous pressure—a unique mechanism among glaucoma drops. Side effects include conjunctival redness (the most common), corneal deposits (verticillata), and conjunctival bleeding.

Fixed-dose combination drops reduce the number of daily instillations and improve adherence. Netarsudil/latanoprost (Roclatan®) combines a ROCK inhibitor with a prostaglandin and achieves 31–37% IOP reduction in a single nightly drop, making it one of the most potent topical options available. Other common combinations include dorzolamide/timolol (Cosopt®), brimonidine/timolol (Combigan®), and brinzolamide/brimonidine (Simbrinza®). Two drugs with novel mechanisms received FDA approval in 2017 and 2022 respectively: latanoprostene bunod (Vyzulta®) combines a prostaglandin with a nitric oxide donor that relaxes trabecular meshwork cells through a separate cyclic guanosine monophosphate (cGMP) pathway, achieving 32–34% IOP reduction; omidenepag isopropyl (Omlonti®) activates the EP2 receptor rather than the FP receptor used by traditional prostaglandins, reducing IOP by 28–29% with less periorbital fat atrophy. Bimatoprost intracameral implant (Durysta®), FDA-approved in 2020, is a biodegradable implant injected directly into the anterior chamber that releases bimatoprost continuously for approximately six months, reducing IOP by approximately 7.5 mmHg from a single procedure; it requires monitoring for corneal endothelial cell effects. The travoprost intracameral implant (iDose® TR) received FDA approval in 2023 as a sustained-release alternative.

Selective laser trabeculoplasty (SLT) is an in-office laser treatment applied to the trabecular meshwork that stimulates biological changes and increases aqueous outflow. The LiGHT Trial (2019) demonstrated that SLT is as effective as prostaglandin eye drops for IOP control at three years and is now considered a first-line alternative to eye drops for many patients. SLT reduces IOP by 20–30%, can be repeated approximately every two to five years, and has an excellent safety profile. It is performed without incisions in a brief office visit under topical anesthesia.

Laser peripheral iridotomy (LPI) is the first-line definitive treatment for acute angle-closure crisis, chronic angle-closure, and for prophylaxis in individuals with narrow angles or primary angle-closure suspects. A small opening is made in the peripheral iris with a laser, bypassing the pupillary block and allowing aqueous humor to equalize pressure between the posterior and anterior chambers. LPI is performed in the office and successfully aborts acute angle-closure in 42–72% of cases when performed promptly.

Cyclophotocoagulation (CPC) uses laser energy to ablate the ciliary body—the tissue that produces aqueous humor—thereby reducing IOP by decreasing fluid production. Conventional transscleral CPC is reserved for refractory, advanced, or end-stage glaucoma where other options have failed. Micropulse CPC applies sub-threshold energy in short pulses, sparing more tissue and reducing the risk of hypotony (dangerously low eye pressure) while still reducing IOP.

A family of procedures characterized by an internal (ab interno) approach through a small corneal incision, minimal disruption of the conjunctiva (needed for future filtration surgery), and a substantially safer profile than traditional glaucoma surgery. MIGS procedures are generally indicated for mild-to-moderate open-angle glaucoma and are frequently combined with cataract surgery when the patient needs both. IOP reduction is typically less than traditional surgery, but with substantially fewer serious complications.

• Trabecular bypass and canal enhancement procedures: The iStent inject® W (Glaukos) places two micro-bypass titanium stents through the trabecular meshwork into Schlemm’s canal; FDA-approved with seven-year data showing 83.7% of eyes maintaining at least 20% IOP reduction. The Hydrus® Microstent (Alcon) is an intracanalicular scaffold spanning 90 degrees of Schlemm’s canal, achieving 34% IOP reduction and demonstrated superiority to iStent in the HORIZON randomized controlled trial.
• Goniotomy procedures: The Kahook Dual Blade (KDB) and Trabectome excise a strip of trabecular meshwork using different cutting mechanisms (surgical blade and electrosurgery, respectively), opening direct access to Schlemm’s canal. Both achieve approximately 24–25% IOP reduction. Gonioscopy-assisted transluminal trabeculotomy (GATT) threads a suture around the full 360 degrees of Schlemm’s canal for complete trabeculotomy, achieving 36.5% IOP reduction at low device cost.
• Canaloplasty: Ab interno canaloplasty (ABiC) uses viscoelastic dilation of Schlemm’s canal and all its collector channels to restore the natural drainage pathway, achieving approximately 36% IOP reduction.
• Subconjunctival bleb-forming MIGS: The Xen® Gel Stent (AbbVie) is a 6 mm gelatin stent placed from inside the eye into the subconjunctival space, creating a filtering bleb similar to trabeculectomy; achieves approximately 38.8% IOP reduction with adjunct mitomycin C. The PreserFlo™ MicroShunt (Santen) uses a poly(styrene-block-isobutylene-block-styrene)—SIBS—polymer subconjunctival tube with comparable results in some studies.

Trabeculectomy is the gold standard incisional glaucoma surgery and the most commonly performed filtration procedure worldwide. A partial-thickness opening is created in the scleral wall, allowing aqueous humor to flow from the anterior chamber into a reservoir under the conjunctiva (called a filtering bleb), lowering IOP to target levels typically in the 10 to 14 mmHg range for high-risk patients. Antiscarring agents—mitomycin C (MMC) or 5-fluorouracil (5-FU)—are applied during surgery to prevent fibrosis from sealing the drainage opening. Complications include low eye pressure (hypotony), bleb infections (blebitis), failure from scarring, cataract acceleration, and the rare but serious risk of endophthalmitis.

Glaucoma drainage devices (tube shunts) use a silicone tube to channel aqueous humor from the anterior chamber to a plate fixed to the scleral surface, creating an external drainage bleb. The Ahmed® Glaucoma Valve includes a flow-restricting valve that reduces the risk of early postoperative hypotony. The Baerveldt® implant has a larger plate surface area for greater long-term IOP control. Tube shunts are particularly useful in eyes that have previously undergone trabeculectomy or other conjunctival surgery. The Tube Versus Trabeculectomy (TVT) Trial demonstrated that tube shunts and trabeculectomy produce similar IOP outcomes at five years, with tube shunts showing a lower failure rate in previously operated eyes.

Cataract extraction (phacoemulsification with intraocular lens implantation) is the primary treatment for patients with primary angle-closure or PACG when a visually significant cataract is present, because removing the thick crystalline lens substantially widens the anterior chamber angle and often meaningfully reduces IOP.

For patients who have already experienced significant, irreversible visual field loss, low vision rehabilitation can meaningfully restore independence and daily function. Optical magnifiers (handheld and stand-mounted) enhance remaining central vision. Electronic video magnifiers and smartphone accessibility features provide flexible magnification for reading and daily tasks. Orientation and mobility training teaches white cane skills and strategies for navigating environments with peripheral field loss. Bioptic telescopes—miniature telescopes mounted in spectacle lenses—allow some patients with peripheral field loss to continue driving in states where bioptic driving is permitted. Lighting modifications, high-contrast materials, and home environment adaptations support safety and independence. Driving safety evaluation is an important and often emotionally difficult conversation for patients with significant peripheral field loss. Low vision specialists, occupational therapists, and orientation and mobility specialists work together to maximize functional vision and quality of life.

Regular aerobic exercise—targeting at least 5,000 additional steps per day above baseline—is associated with approximately 10% slower visual field loss in treated glaucoma patients and is one of the few lifestyle factors with documented benefit. Patients should avoid sustained Valsalva maneuvers (straining, heavy lifting), prolonged face-down positioning, and tight neckties or collars, as these can transiently raise IOP. Yoga inversions (head below heart) can spike IOP significantly and should be used cautiously by patients with advanced glaucoma. Maintaining good sleep habits and side-sleeping on the less-affected eye (when one eye is more advanced) is reasonable. Most importantly, consistent use of prescribed eye drops—which requires one or two brief applications each day for the rest of one’'s life—remains the most modifiable and impactful factor in preventing further vision loss.

Glaucoma is a chronic, lifelong condition requiring continuous management—but it is not a condition that inevitably leads to blindness. The majority of patients diagnosed early and adherent to treatment can preserve functional vision and maintain a high quality of life for decades. The range of outcomes is broad: patients with mild glaucoma detected early and managed consistently may experience minimal functional impact on work, driving, reading, and daily life. Those with advanced disease at the time of diagnosis face greater challenges, and the vision already lost before diagnosis cannot be restored.

The most impactful factors within a patient’s control are consistent use of prescribed IOP-lowering medications (even when the eye feels entirely normal—glaucoma causes no discomfort until very late), keeping all scheduled monitoring appointments (including visual field tests and OCT imaging), promptly reporting any changes in vision, and maintaining regular aerobic physical activity. Many patients find the lifelong daily eye drop routine challenging to sustain, particularly when there are no symptoms to remind them. Discussing adherence strategies with your ophthalmologist—including simplifying regimens with combination drops, setting phone reminders, and using adherence-tracking devices—is an important and legitimate part of glaucoma management.

It is important to acknowledge the significant health equity dimension of glaucoma in the United States. Black and Hispanic/Latino Americans face substantially higher rates of glaucoma, are more likely to be at an advanced stage when first diagnosed, and face greater barriers to consistent follow-up care. This is a structural inequity that Montefiore Einstein is committed to addressing through community-based screening programs, accessible care, and culturally competent patient education. If you or a family member falls into a high-risk demographic group, advocating for regular dilated eye examinations beginning at age 40 is one of the most important proactive health steps you can take.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of glaucoma and related eye disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.